ESR1 and breast cancer: This discovery has led us to identify several FDA-approved drugs, originally designed for other purposes, that exhibit ‘anti-estrogen-like’ properties and can induce ERα degradation, effectively blocking the proliferation of various BC cell lines (10–17).